TY - JOUR
T1 - Ebolavirus vaccines for humans and apes
AU - Fausther-Bovendo, Hugues
AU - Mulangu, Sabue
AU - Sullivan, Nancy J.
PY - 2012/6
Y1 - 2012/6
N2 - Because of high case fatality proportions, person-to-person transmission, and potential use in bioterrorism, the development of a vaccine against ebolavirus remains a top priority. Although no licensed vaccine or treatment against ebolavirus is currently available, progress in preclinical testing of countermeasures has been made. Here, we will review ebolavirus vaccine candidates and considerations for their use in humans and wild apes.
AB - Because of high case fatality proportions, person-to-person transmission, and potential use in bioterrorism, the development of a vaccine against ebolavirus remains a top priority. Although no licensed vaccine or treatment against ebolavirus is currently available, progress in preclinical testing of countermeasures has been made. Here, we will review ebolavirus vaccine candidates and considerations for their use in humans and wild apes.
UR - http://www.scopus.com/inward/record.url?scp=84862861509&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84862861509&partnerID=8YFLogxK
U2 - 10.1016/j.coviro.2012.04.003
DO - 10.1016/j.coviro.2012.04.003
M3 - Review article
C2 - 22560007
AN - SCOPUS:84862861509
SN - 1879-6257
VL - 2
SP - 324
EP - 329
JO - Current Opinion in Virology
JF - Current Opinion in Virology
IS - 3
ER -